Clinical trial
Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder
Abstract
This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
PreprintPsilocybin
Confirmatory factor analysis of Mystical Experience in Freediving as a recreative way to higher efficiency in sport performance and planet saving and money making
ArticlePsilocybin
Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease.
ArticlePsilocybin